Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.41 |
| ▸ | ACACB | O00763 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 4/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 6/20 | 0.33 |
| ▸ | PIKFYVE | Q9Y2I7 | 1/20 | 0.33 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.33 |
| ▸ | PIP4K2B | P78356 | 1/20 | 0.33 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.33 |
| ▸ | TGFBR2 | P37173 | 2/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
| ▸ | HPGDS | O60760 | 1/20 | 0.30 |
| ▸ | CDK8 | P49336 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3808160 | 0.90 | TGFBR1 (0.42) | TGFBR1CYP3A4CYP2C8ACACBJAK1 | |
| SCHEMBL4162984 | 0.89 | TGFBR1 (0.42) | TGFBR1CYP3A4CYP2C8ACACBJAK1 | |
| SCHEMBL4150473 | 0.87 | TGFBR1 (0.42) | TGFBR1CYP3A4CYP2C8ACACBJAK1 | |
| SCHEMBL4154782 | 0.83 | TGFBR1 (0.47) | TGFBR1CYP3A4CYP2C8PIKFYVEPIP4K2A | |
| SCHEMBL3670900 | 0.82 | CYP3A4 (0.42) | TGFBR1CYP3A4CYP2C8ACACBJAK1 | |
| SCHEMBL4156980 | 0.82 | ACACB (0.43) | TGFBR1CYP3A4CYP2C8ACACBJAK1 | |
| SCHEMBL4167375 | 0.82 | TGFBR1 (0.41) | TGFBR1CYP3A4CYP2C8ACACBJAK1 | |
| SCHEMBL4155573 | 0.82 | TGFBR1 (0.41) | TGFBR1CYP3A4CYP2C8ACACBJAK1 | |
| SCHEMBL3795813 | 0.82 | TGFBR1 (0.41) | TGFBR1CYP3A4CYP2C8ACACBJAK1 | |
| SCHEMBL4148983 | 0.81 | TGFBR1 (0.48) | TGFBR1CYP3A4CYP2C8ACACBJAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8314112-B2 | Pyrrolopyrimidines and pyrrolopyridines | NOVARTIS AG (CH) | 2012-11-20 | — | — | US | disclosed |
| US-20090181941-A1 | Pyrrolopyrimidines and Pyrrolopyridines | NOVARTIS AG (CH) | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181941-A1 | Pyrrolopyrimidines and Pyrrolopyridines | ALK, ACVR1, PTPN4 | TGFBR1 128/4885CYP3A4 111/4885CYP2C8 1297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.